BioAscent appoints new CEO

0
79

BioAscent Discovery has announced the appointment of Paul Smith as CEO, in preparation for the expansion of BioAscent’s discovery services offering. Paul – an experienced senior management and BD executive in the pharmaceutical/CRO arena – brings comprehensive knowledge of the drug development process, from discovery to clinical research, gained over three decades in the industry. Prior to joining BioAscent, he was CEO of CXR Biosciences, a Dundee-based ADME-Tox CRO which he successfully re-engineered from a loss-making business into a focused preclinical CRO with sector-beating profitability, and subsequently sold to Concept Lifesciences.

Comments

comments